Theravance Biopharma Statistics
Total Valuation
TBPH has a market cap or net worth of $884.18 million. The enterprise value is $535.09 million.
| Market Cap | 884.18M |
| Enterprise Value | 535.09M |
Important Dates
The last earnings date was Monday, August 10, 2026, before market open.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TBPH has 51.92 million shares outstanding. The number of shares has increased by 3.94% in one year.
| Current Share Class | 51.92M |
| Shares Outstanding | 51.92M |
| Shares Change (YoY) | +3.94% |
| Shares Change (QoQ) | +0.76% |
| Owned by Insiders (%) | 6.24% |
| Owned by Institutions (%) | 49.26% |
| Float | 25.86M |
Valuation Ratios
The trailing PE ratio is 16.30 and the forward PE ratio is 4.29.
| PE Ratio | 16.30 |
| Forward PE | 4.29 |
| PS Ratio | 8.48 |
| Forward PS | 9.26 |
| PB Ratio | 3.05 |
| P/TBV Ratio | 3.05 |
| P/FCF Ratio | 16.45 |
| P/OCF Ratio | 16.45 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 48.20, with an EV/FCF ratio of 9.96.
| EV / Earnings | 9.94 |
| EV / Sales | 5.13 |
| EV / EBITDA | 48.20 |
| EV / EBIT | 56.03 |
| EV / FCF | 9.96 |
Financial Position
The company has a current ratio of 13.54, with a Debt / Equity ratio of 0.13.
| Current Ratio | 13.54 |
| Quick Ratio | 13.26 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 3.47 |
| Debt / FCF | 0.72 |
| Interest Coverage | 8.27 |
Financial Efficiency
Return on equity (ROE) is 20.91% and return on invested capital (ROIC) is -3.66%.
| Return on Equity (ROE) | 20.91% |
| Return on Assets (ROA) | 1.33% |
| Return on Invested Capital (ROIC) | -3.66% |
| Return on Capital Employed (ROCE) | 2.18% |
| Weighted Average Cost of Capital (WACC) | 5.48% |
| Revenue Per Employee | $1.16M |
| Profits Per Employee | $597,867 |
| Employee Count | 90 |
| Asset Turnover | 0.23 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TBPH has paid $5.11 million in taxes.
| Income Tax | 5.11M |
| Effective Tax Rate | 8.67% |
Stock Price Statistics
The stock price has increased by +23.45% in the last 52 weeks. The beta is 0.25, so TBPH's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | +23.45% |
| 50-Day Moving Average | 16.94 |
| 200-Day Moving Average | 17.29 |
| Relative Strength Index (RSI) | 61.05 |
| Average Volume (20 Days) | 516,070 |
Short Selling Information
The latest short interest is 4.17 million, so 8.03% of the outstanding shares have been sold short.
| Short Interest | 4.17M |
| Short Previous Month | 4.31M |
| Short % of Shares Out | 8.03% |
| Short % of Float | 16.12% |
| Short Ratio (days to cover) | 5.66 |
Income Statement
In the last 12 months, TBPH had revenue of $104.31 million and earned $53.81 million in profits. Earnings per share was $1.05.
| Revenue | 104.31M |
| Gross Profit | 78.30M |
| Operating Income | 9.55M |
| Pretax Income | 58.92M |
| Net Income | 53.81M |
| EBITDA | 11.10M |
| EBIT | 9.55M |
| Earnings Per Share (EPS) | $1.05 |
Balance Sheet
The company has $387.66 million in cash and $38.57 million in debt, with a net cash position of $349.09 million or $6.72 per share.
| Cash & Cash Equivalents | 387.66M |
| Total Debt | 38.57M |
| Net Cash | 349.09M |
| Net Cash Per Share | $6.72 |
| Equity (Book Value) | 289.71M |
| Book Value Per Share | 5.58 |
| Working Capital | 385.90M |
Cash Flow
In the last 12 months, operating cash flow was $53.74 million and capital expenditures -$8,000, giving a free cash flow of $53.73 million.
| Operating Cash Flow | 53.74M |
| Capital Expenditures | -8,000 |
| Depreciation & Amortization | 1.55M |
| Net Borrowing | n/a |
| Free Cash Flow | 53.73M |
| FCF Per Share | $1.03 |
Margins
Gross margin is 75.06%, with operating and profit margins of 9.16% and 51.58%.
| Gross Margin | 75.06% |
| Operating Margin | 9.16% |
| Pretax Margin | 56.48% |
| Profit Margin | 51.58% |
| EBITDA Margin | 10.64% |
| EBIT Margin | 9.16% |
| FCF Margin | 51.51% |
Dividends & Yields
TBPH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.94% |
| Shareholder Yield | -3.94% |
| Earnings Yield | 6.09% |
| FCF Yield | 6.08% |
Analyst Forecast
The average price target for TBPH is $17.67, which is 3.76% higher than the current price. The consensus rating is "Hold".
| Price Target | $17.67 |
| Price Target Difference | 3.76% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | -5.87% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TBPH has an Altman Z-Score of 1.36 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.36 |
| Piotroski F-Score | 6 |